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Ex vivo gene therapy with adenovirus-mediated
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Objective: Endovascular treatment of cerebral aneurysm is safe and effective, but recurrence of disease is frequent
compared with results with surgery. The purpose of this study was to determine the effects of recombinant transforming
growth factor 1 (rTGF1) secreted by transplanted autologous vascular smooth muscle cells (VSMC) on results of
endovascular treatment.
Methods: VSMC from canine femoral arteries were infected with adenovirus vector encoding rTGF1/green fluorescent
protein (rTGF1/GFP) or GFP only. rTGF1 production was measured with an enzyme-linked immunosorbent assay,
and autocrine and paracrine effects of rTGF1 on cell functions were quantified with a proliferation assay and collagen
synthesis. A bilateral carotid aneurysm model was used to compare angiographic and pathologic results after emboliza-
tion with sponges seeded (n 14) or not seeded (n 34) with VSMC expressing TGF1 or GFP (n 7 each). Transgene
retention was confirmed with Western blot analysis.
Results: In vitro, TGF1 production varied from 0.9 to 180 ng/mL/d with increasing multiplicity of infection (MOI).
Collagen synthesis was doubled at low (<300) MOI and increased by one and a half times at high (>300) MOI. rTGF1
was biologically active, as shown with the mink lung epithelial cell proliferation assay. VSMC grafts showed effective GFP
expression up to 3 weeks after transplantation. Angiographic results were improved and neointima thickness was
increased with cellular grafts, as compared with controls, but there was no significant difference between aneurysms
treated with VSMC encoding rTGF1/GFP or GFP vectors.
Conclusion: Cellular grafts can promote healing of aneurysms, but overexpression of rTGF1/GFP did not demonstrate
added benefits in this model. (J Vasc Surg 2003;38:576-83.)
Endovascular treatment of intracranial aneurysm is ef-
fective in preventing recurrent bleeding after subarachnoid
hemorrhage, but recanalization and aneurysm recurrence
are frequent.1 Healing phenomena after coil embolization
include thrombus formation, vascular smooth muscle cell
(VSMC) or myofibroblast migration, and production of
extracellular matrix, eg, collagen. Migration of endothelial
cells, essential to maintain the nonthrombogenic integrity
of the vessel walls, occurs early2 and is associated with
recanalization and recurrence of aneurysm.3 These nonspe-
cific phenomena, which are essential to vascular integrity,
may also be involved in healing mechanisms, or their fail-
ure, after stent-graft repair of aortic aneurysm.4-9
Numerous growth factors, eg, platelet-derived growth
factor-BB and TGF1 have been implicated in neointima
formation and vascular remodeling.10,11 TGF1 is a 25
kDa homodimeric polypeptide, belonging to a superfamily
of multifunctional cytokines, that participates in a wide
range of biologic activities, eg, normal development and
wound healing, as well as pathologic processes. TGF1 can
positively or negatively regulate systems involved in cell
proliferation, migration, extracellular matrix synthesis, and
apoptosis of VSMC and endothelial cells.12,13 Overexpres-
sion of recombinant transforming TGF1 (rTGF1) may
promote healing of aneurysms by increasing extracellular
matrix deposition and by inhibiting endothelial cells asso-
ciated with recanalization.3,14
We have previously shown that cells recovered from the
neck of treated aneurysms are -actin positive and
PDGF-BB and TGF1 sensitive
11; local delivery of TGF1
can increase neointimal thickness11; autologous VSMC
grafts improve angiographic results after embolization.15
To improve outcome of aneurysm after endovascular treat-
ment, we now propose an ex vivo gene therapy that uses
VSMC infected with adenovirus vector encoding rTGF1/
green fluorescent protein (GFP) or GFP alone. Our goals
were to define optimal multiplicity of infection (MOI) for
vector infection, measure rTGF1 production, study auto-
crine and paracrine effects of rTGF1 on cell functions, and
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determine in vivo gene retention. Finally, we wanted to
assess feasibility of ex vivo gene therapy with rTGF1 and
its potential to promote healing after endovascular treat-
ment of aneurysm.
METHODS
Cell cultures. VSMC were harvested from the left
femoral artery of each dog and cultured with the previously
described explantation technique.16 In brief, arteries were
harvested under sterile condition and maintained in sterile
Dulbecco modified Eagle medium (DMEM; Wisent Inc,
St.-Bruno, Quebec, Canada) supplemented with 10% fetal
bovine serum (FBS) and antibiotics (Wisent Inc). Twenty-
four explants (1  1 mm) were prepared from the medial
layer of each artery and placed in separate wells of 24-well
plates. Cells between passages 1 to 5 were used for in vitro
and in vivo experiments. Mink lung epithelial cells (MLEC-
32), a gift from Dr Bernard Massie (Institut de Recherche
en Biotechnologie, Montreal, Canada) stably transfected
with luciferase complementary DNA under the control of a
rTGF1 responsive promoter, a truncated plasminogen
activator inhibitor–1 promoter, were cultured in DMEM
supplemented with FBS and antibiotics, as previously de-
scribed, and used for the inhibition of proliferation assay.17
Adenoviral infection. VSMC were infected by incu-
bation for 2 hours at 37°C with purified adenoviral vectors
encoding either rTGF1/GFP (AdTR5-DCTGFbetaGFP:
1.7  1011 plaque-forming units [pfu] per milliliter) or
GFP (AdTR5-GFPq: 6.5 1010 pfu/mL) for a MOI (ratio
of viral particles per cell) of 300. For better absorption,
mechanical agitation was required every 15 minutes. The
adenovirus vectors were a gift from Dr Bernard Massie
(Institut de Recherche en Biotechnologie, Montreal, Can-
ada). Both transfer vectors have a tetracycline-regulated
expression. For constitutive expression of these vectors, a
double infection is required, using a vector with a consti-
tutive expression of tetracycline (AdCMV-tTA: 1.2 1012
pfu/mL). For these transacting systems, the same MOI was
used. Efficiency of infection was quantified with the ratio of
GFP-positive and GFP-negative cells.
Enzyme-linked immunosorbent assay, DNA, and
collagen synthesis. Supernatants from transfected VSMC
were collected every 24 hours for 26 consecutive days and
stored at 20°C. Enzyme-linked immunosorbent assay
(ELISA) for immunoreactive rTGF1 was performed as
recommended by the manufacturer (R&D Systems, Min-
neapolis, Minn). Activation of rTGF1 to the immunore-
active form was accomplished with acidification, and
ELISA was used to measure total rTGF1. DNA synthesis
was assessed for all cell types with 3H-thymidine incorpo-
ration (Pharmacia, Kalamazoo, Mich) exactly as de-
scribed.18 Collagen synthesis by VSMC expressing
rTGF1/GFP vector was measured with
3H-proline incor-
poration (Pharmacia) according to the method of Koyano
et al.19 Recombinant human TGF1 (rhTGF1; R&D
systems) was used as control for all in vitro experiments
unless otherwise indicated. For all experiments, untreated
cells (without vector) were used as negative controls, and
results were expressed as percentage of negative controls.
Tridimensional VSMC grafts. VSMC expressing ei-
ther rTGF1/GFP or GFP vectors at MOI 300 were
seeded onto collagen sponges as described.15 MOI of 300
was chosen because in vitro production of rTGF1 was
maximal for 26 days, whereas higher MOI exhibited an
acute drop in production after day 6 (Fig 1). In brief,
autoclaved absorbable gelatin sponge fragments, measur-
ing 10  10  6 mm, were placed in 24-well plates with 1
mL of DMEM containing fibrinogen (2 mg/mL), and 4
106 infected cells suspended in 100 L of DMEM were
added to each well. After 2 hours, seeded sponges were
transferred in 6-well plates containing an excess of fresh
DMEM. Fibrinogen-coated sponges were prepared simi-
larly, without adding cells, and control sponges were rehy-
drated for 10 minutes in phosphate-buffered saline solution
(Wisent Inc) 2 hours before the surgical procedure. In vivo
studies included four distinct categories separated into two
groups. Treated groups included sponges seeded with
VSMC overexpressing rTGF1/GFP or sponges seeded
with VSMC overexpressing GFP only, whereas the control
group included fibrinogen-coated or bare sponges. For
each sponge implanted in vivo, two identical sponges were
studied in vitro, one at transplantation (CTL0) and the
other kept in vitro until the day of euthanasia (CTL1). In
vitro control sponges were frozen in liquid nitrogen and
kept at 80°C until final analysis of in vivo sponges.
Western blot analysis. The level of rTGF1 expres-
sion of in vivo grafts was assessed with Western blot analysis
on specimens harvested at the neck of aneurysms and
Fig 1. Time course of immunoreactive recombinant transforming
growth factor-1 (rTGF1) measured in e supernatant of vascular
smooth muscle cells infected with rTGF1/green fluorescent pro-
tein vector, with multiplicity of infection (MOI) varying from 0 to
900. Aliquots from supernatants were collected every 24 hours,
and mature rTGF1 were quantified with enzyme-linked immu-
nosorbent assay on days 1, 6, 12, 20, and 26.
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compared with control sponges kept in culture for the same
period, ie, to CTL0 and CTL1. Specimens were lysed in
electrophoresis buffer (50 mmol/L of HEPES, 150
mmol/L of NaCl2, 1 mmol/L of EDTA, 10% glycerol, 25
mol/L of -glycerophosphate, 1 mmol/L of dithiothre-
itol, 1 mmol/L of sodium orthovanadate, 1 mmol/L of
sodium fluoride, 1% Tween 20, 1 mmol/L of phenylmethyl
sulfonyl fluoride, 1 g/mL of leupeptin, and 1 g/mL of
aprotinin; Sigma, St Louis, Mo), homogenized, and boiled.
Proteins (25 g) were separated with sodium dodecylso-
dium polyacrylamide electrophoresis, electrophoretically
transferred to polyvinylidene diflouride membranes (Bio-
Rad Laboratories, Hercules, Calif), and blocked 1 hour in
phosphate-buffered saline solution containing nonfat milk
(5%) and Tween 20 (0.05%). Blots were then incubated
with TGF1 antibody (1:1000; Promega, Madison, Wis)
overnight. Membranes were then incubated for 1 hour with
horseradish peroxidase–conjugated donkey anti-rabbit an-
tibody (1:20,000 dilution; Amersham, Arlington Heights,
Ill). Blots were developed by a chemiluminescent method
described by the manufacturer (ECL method; Amersham).
Normal VSMC (25 g) were used as negative control, and
rTGF1 (50 ng; Chemicon, Temecula, Calif) was used as
positive control.
Animal model and pathologic studies. The lateral
wall venous pouch carotid aneurysm model and the per-
operative techniques with collagen sponges have been de-
scribed previously.15,20 Protocols for animal experimenta-
tion were approved by the Institutional Animal Care
Council of the University of Montreal Research Centre and
in accordance with the guidelines of the Canadian Council
on Animal Care. Lateral wall aneurysms were constructed
on each common carotid artery with the technique of
German and Black as modified by Graves et al.21 In brief,
with the animal under general anesthesia, two segments of
the same external jugular vein were harvested for venous
pouch construction. The common carotid artery was oc-
cluded temporarily, a 5 mm arteriectomy was performed,
and anastomosis of the venous pouch to the arteriectomy
site was completed. Per-operative embolization in the
treated and control groups was performed with introduc-
tion of sponges through the vein pouch, before clip closure
of the fundus. The sponge was pushed toward the neck
from the end opposite the anastomosis, in an attempt to
completely occlude the aneurysm. Embolization was ac-
complished in a random and blind manner for each animal.
To minimize risk for immune reaction, aneurysms were
treated with sponges seeded with VSMC harvested from
the animal’s own femoral artery. Carotid angiography was
performed immediately after surgery and before euthanasia
for follow-up results. Angiographic results were scored
according to a classification previously described.15,20 A
score of 0 was attributed to complete obliteration, 1 to
proximal or distal fissures, 2 to opacification of the neck,
and 3 to residual or recurrent aneurysm. Before fixing
tissues in 10% buffered formalin phosphate (Fisher Scien-
tific, Nepean, Ontario, Canada), macroscopic and fluores-
cent photographs of the aneurysm necks were taken. Half
of the specimens were frozen in liquid nitrogen and kept at
80°C for Western blot analysis. Axial sections at the
aneurysm necks were obtained from the other half and
stained with hematoxylin-phloxine-saffron and Movat pen-
tachrome stains, as described.20
Statistical analysis. In vitro results were expressed as
mean SD and compared with analysis of variance and the
Student t test; P  .05 was considered statistically signifi-
cant. Angiographic scores were expressed as median values
and compared with the Mann-Whitney, Kruskal-Wallis,
and Wilcoxon tests, as appropriate; P .05 was considered
statistically significant.
RESULTS
Expression of GFP and production of rTGF1 by
cultured VSMC. Fluorescent microscopy showed green
VSMC 48 hours after infection, proving efficiency of gene
expression (data not shown). Coexpression of GFP in a
dicistronic form (TGF1/GFP expression) reduced the
level of fluorescence when compared with GFP expression
alone. Fluorescence index and infection efficiency (75%-
85%) increased in proportion with increasing MOI, to
MOI 900 with both vectors (data not shown).
rTGF1 produced by VSMC was quantified with
ELISA. A proportional increase in rTGF1 production
according to increasing MOI was measured on days 1 to 26
and reached 180 ng/mL with the highest MOI (Fig 1). At
MOI ranging 100 to 300, secretion peaked on day 12, and
returned to initial level of secretion on day 20. At highest
MOI (600 and 900) rTGF1 secretion rapidly decreased
on day 6, reaching levels observed with lower MOI. Quan-
tification of immunoreactive rTGF1 performed on days 1,
6, 12, 20, and 26 with the supernatant of VSMC encoding
GFP vector at MOI varying from 0 to 900 showed the same
basal concentration of TGF1 found in unconditioned
culture medium (DMEM plus 10% FBS; data not shown).
In vitro biologic effects of rTGF1. DNA synthesis
of VSMC containing either rTGF1/GFP or GFP vectors
was proportionally decreased with increasing MOI (Fig 2,
A and B, respectively). Inhibition of 3H-thymidine incor-
poration in VSMC was more pronounced with GFP vector
than with rTGF1/GFP vector.
Collagen synthesis by VSMC expressing rTGF1 vec-
tor significantly increased with increasing MOI (Fig 3, A).
At MOI 100, collagen synthesis reached maximal produc-
tion: 200% increase in production, as compared with neg-
ative controls. With increasing MOI, collagen synthesis
decreased progressively, but still remained superior to neg-
ative controls.
DNA synthesis of MLEC-32 was decreased by 90%
when compared with control, with concentrations of
rTGF1 varying from 0.1 to 10 ng/mL (data not shown).
The proliferation assay of MLEC-32 with supernatants of
VSMC expressing rTGF1/GFP vector at MOI 300
showed decreased 3H-thymidine incorporation with 0.1 or
1 ng/mL of rTGF1 (Fig 3, B). rTGF1 (0.1 ng/mL)
measured with ELISA caused inhibition of 3H-thymidine
incorporation that reached 90% on days 1 and 6, 80% on
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day 12, and 40% on days 20 and 26. With 1 ng/mL of
rTGF1, inhibition of DNA synthesis by MLEC-32
reached 40% on day 1, 85% on days 6 and 12, 60% on day
20, and 20% on day 26. The same experiments were re-
peated with supernatants harvested from cultured VSMC
encoding rTGF1/GFP at MOI 200 and 600. At MOI
200, antiproliferative effects were observed on days 1, 6,
and 12 with both concentrations (0.1 and 1 ng/mL; data
not shown). With MOI 600, DNA synthesis was inhibited
only on days 1 and 6 with both concentrations (data not
shown).
Angiographic results. Initial angiographic score im-
proved in aneurysms treated with cell grafts (TGF1/GFP
[n 	 7] or GFP [n 	 7]), as compared with fibrinogen-
coated sponges (n 	 17 aneurysms) or bare sponges (n 	
17 aneurysms; P  .01; Table).
Aneurysms treated with sponges seeded with recombi-
nant VSMC (expressing TGF1/GFP or GFP vectors)
showed improved angiographic results at 3 weeks, as com-
pared with immediate results (P .01). Aneurysms treated
Fig 2. DNA synthesis of vascular smooth muscle cells infected
with recombinant transforming growth factor-1 (A) and green
fluorescent protein vector (B) with multiplicity of infection (MOI)
varying from 0 to 900. Results are expressed as percentage of
control 3H-thymidine incorporation obtained with MOI 0/0.5%
fetal bovine serum (mean SD). *P .05 versus controls. **P
.01 versus controls.
Fig 3. A, Collagen synthesis of vascular smooth muscle cells
infected with recombinant transforming growth factor-1
(rTGF1)/green fluorescent protein (GFP) vector at multiplicity
of infection (MOI) ranging from 0 to 900. Results are expressed as
percentage of control 3H-proline incorporation obtained with
MOI 0/0.5% fetal bovine serum (FBS; mean  SD). *P  .05
versus controls. **P  .01 vs controls. B, DNA synthesis of mink
lung epithelial cells (MLEC-32) in response to 0.1 or 1 ng/mL of
rTGF1 produced by vascular smooth muscle cells expressing
rTGF1/GFP vector at MOI 300 at days 1, 6, 12, 20, and 26 after
infection. Results are expressed as percentage of 3H-thymidine
incorporation obtained with 0% FBS (mean  SD). *P  .05
versus controls. **P  .01 versus controls.
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with fibrinogen-coated sponges or bare sponges showed no
significant change in angiographic score over time. At 3
weeks there was no significant difference in angiographic
score between grafts expressing rTGF1/GFP vector and
grafts expressing GFP vector only (P 
 .3). Angiographic
score at 3 weeks was significantly better with recombinant
cellular grafts, as compared with fibrinogen-coated sponges
or bare sponges (P  .01).
In vivo findings. Fluorescent microscopy of fresh
specimens harvested from the neck of treated aneurysms at
3 weeks after embolization showed numerous GFP-posi-
tive VSMC with both vectors (Fig 4, A and B). Fluores-
cence index decreased over time with both vectors, but
when compared, fluorescence was more intense with GFP
expressed as a single cistron (data not shown). No fluores-
cence was observed with specimens harvested from the
neck of aneurysms treated with fibrinogen-coated sponges
or bare sponges (Fig 4, C).
Macroscopic photographs of the neck of aneurysms
harvested at 3 weeks showed complete or nearly complete
obliteration of the neck of aneurysms treated with sponges
seeded with VSMC encoding rTGF1/GFP or GFP vec-
tors (Fig 4, D and E), whereas aneurysms treated with
fibrinogen-coated sponges or bare sponges showed recur-
rence of disease (Fig 4, F).
Histologic studies of specimens treated with recombi-
nant cell grafts harvested at 1 week showed implanted
cellular sponges covered with thrombus and early neoin-
tima formation (data not shown), compared with fibrino-
gen-coated sponges or bare sponges. At 3 weeks the neo-
intima was thicker and contained more cells and
extracellular matrix (Fig 4, G and H). There was no signif-
icant difference at 3 weeks between sponges seeded with
VSMC expressing rTGF1/GFP or GFP vectors. Axial
sections of aneurysms treated with cell grafts showed a thick
cellular neointima, whereas specimens from aneurysms
treated with fibrinogen-coated sponges or bare sponges
showed disease recurrence and a thin neointima (Fig 4,
G-I).
In vivo expression of rTGF1 vector. Western blot
analysis was performed on specimens harvested at the neck
of aneurysms treated with VSMC expressing rTGF1/GFP
vectors and with in vitro control sponges (CTL0, CTL1) at
1 and 3 weeks (Fig 5, A and B). Analysis showed rTGF1
Fig 4. In vivo findings. A-C, Fluorescent microscopy of fresh
specimens from the neck of aneurysms treated with vascular
smooth muscle cells (VSMC) expressing recombinant transform-
ing growth factor-1 (rTGF1)/green fluorescent protein (GFP)
vector (A) and GFP vector (B) at multiplicity of infection (MOI)
of 300 or with fibrinogen-coated sponge (C), at 3 weeks after
embolization (original magnification 40). D-F, Macroscopic
photographs of fresh specimens at the level of the neck of aneu-
rysms 3 weeks after embolization show nearly complete oblitera-
tion of the neck of aneurysms treated with VSMC grafts expressing
rTGF1)/GFP vector (D) and GFP vector (E) or aneurysm recur-
rence when treated with fibrinogen-coated sponge (F) (original
magnification 20). Histopathologic sections of aneurysms
treated with VSMC grafts expressing rTGF1)/GFP vector (G) or
GFP vector (H) at MOI 300 or with fibrinogen-coated sponge (I),
at 3 weeks after embolization, show neointima formation (arrows)
at the aneurysm neck, carotid artery (a), sponge (s), and recanali-
zation(r). (Movat pentachrome stain; original magnification20.)
Angiographic results
Group Median angiographic score*
No. of aneurysms Initial 1 wk 2 wk 3 wk
Test group
1 Gelfoam  fibrinogen
 VSMC  TGF1
2.0†‡ 2.0 1.0 0.0‡§
2 Gelfoam  fibrinogen
 VSMC  GFP
2.0†‡ 2.0 2.0 0.0‡§
Control group
3 Gelfoam  fibrinogen 3.0† 2.5 3.0 3.0‡§
4 Gelfoam 3.0† 3.0 3.0 3.0‡§
*0, complete obliteration; 1, proximal or distal fissures; 2, opacification of neck; 3, residual or recurrent aneurysm.
†There was a significant difference in initial angiographic score between test and control groups (P  .01, Mann-Whitney test).
‡There was a significant difference in initial and 3-week angiographic scores for test groups (P  .05, Wilcoxon test).
§There was a significant difference in angiographic score at 3 weeks between test and control groups (P .01, Mann-Whitney test and Kruskal-Wallis test), but
no significant difference between groups 1 and 2 and between groups 3 and 4 (P 
 .3, Mann-Whitney test).
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expression only in animals that harbored the transgene.
However, the signal was weaker at 3 weeks than at 1 week
(lanes 3A and 4B). No signal was detected with sponges
seeded with untreated VSMC (lanes 4A or 5B). rTGF1
expression decreased over time in vitro (lanes 2A and 2B)
and in vivo (lanes 3A and 4B).
DISCUSSION
Treating aneurysms classically involves restoration of
vessel wall integrity and of normal flow pattern in the parent
artery. This can be achieved with surgical clipping of cere-
bral aneurysms. In contrast, coil embolization, a less inva-
sive alternative, is frequently incomplete, with residual neck
remaining after treatment.15 Healing phenomena after coil
occlusion of arteries include recanalization and neointima
formation, and both can be found at the neck of the
aneurysm after coil embolization.14 Treatment of abdomi-
nal aortic aneurysm may require conventional surgery, but
in some patients a new nonsurgical treatment, stent-graft
repair, can be performed. This intervention is less invasive,
but is also sometimes subject to aneurysm recurrence.4-9
Disease recurrence after coiling of intracranial aneurysms
and failure of stent-graft repair of aortic aneurysms share
many conceptual difficulties and pathologic features, at
least in experimental models. Abnormal residual flow may
persist after treatment, at the neck of incompletely coiled
aneurysms or in certain types of immediate “leaks” after
stent-graft repair. Crescentic endothelialized channels can
be found within the organized clot that forms after treat-
ment, between the graft or the coil mass and the aneurysm
wall, in both diseases (Fig 6). This pathologic feature,
responsible for persistent patency of endoleaks and of re-
sidual lesions and recurrent disease after coiling, has been
associated with recanalization, a process that we have ex-
tensively studied in canine arterial and aneurysm mod-
els.3,14 Finally, poor or incomplete neointima formation
can be a feature of both conditions.4-9,11,15,20
One way to modulate vascular healing phenomena is
with local delivery of growth factors.11 In vivo effects of
growth factors are difficult to predict, because they are
themselves modulated by multiple cellular and environ-
mental conditions. Although TGF1 seemed effective in
increasing neointimal formation in a porcine aneurysm
model with a strong tendency for spontaneous healing, it
seemed inefficient in a canine model prone to recurrent
disease.11 One reason for this failure may be the difficulty in
producing sustained delivery of a significant amount of
biologically active rTGF1 in species with deficient throm-
bosis after embolization.11 In analogy with other models of
deficient wound healing, cellular grafts could modify the
evolution of aneurysms prone to recur after emboliza-
tion.15 This simplistic approach is, however, difficult to
translate to clinical application, because means for grafting
a large number of cells through microcatheters are limit-
ed.22 Grafting genetically modified cells in aneurysm mod-
els may provide clues to improve healing phenomena after
endovascular treatments. rTGF1 was the first growth fac-
tor that we considered for this approach. It is well known
that this factor is involved in neointima formation and
Fig 5. Western blot analysis. In vivo and in vitro comparison of
recombinant transforming growth factor-1/green fluorescent
protein (rTGF1/GFP) vector expression at 1 week (A) and 3
weeks (B). Cell fractions were harvested from the neck of treated
aneurysms expressing rTGF1/GFP vector, and the other cell
fractions were from sponges kept in vitro as controls. Recombinant
human TGF-1 and normal vascular smooth muscle cells were
used as positive and negative controls, respectively. CTL0, Day of
implantation; CTL1, day of euthanasia.
Fig 6. Macroscopic photographs (A-C) and histopathologic sec-
tions (D-F) at 3 weeks (C, F) and 3 months (A-E) in canine
models show recanalization after platinum coil occlusion of the
maxillary artery (A, D), persistent type II leak after stent-graft
repair of a fusiform aortic aneurysm (B, E), and aneurysm recur-
rence after intraoperative sponge embolization of a lateral wall
carotid aneurysm (C, F). Note endothelialized channels or spaces
responsible for recanalization, leak, or disease recurrence in all
three models (arrows).
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recurrent stenosis23; it is the most potent stimulator of
collagen production, and a well-known inhibitor of en-
zymes involved in matrix degradation.24 It could therefore
favor neointima formation at the aneurysm neck. Further-
more, its inhibitory effects on endothelial cells in certain
models25 suggest that it could repress early endothelializa-
tion of the clot, which seems associated with recanalization
and aneurysm recurrence after coil embolization.3,14
Successful infection of VSMC with adenovirus vector
encoding rTGF1 has rarely been described.
26,27 Chal-
lenges involved in this project include unknown efficiency
of this gene transfer into vascular cells, autocrine and para-
crine effects of rTGF1, in vivo retention of gene transfer,
and viability of cells grafted inside high-flow aneurysms.
The adenovirus vector could infect VSMC with effi-
ciency (rTGF1/GFP in a dicistronic form or GFP as a
single cistron), and the GFP expression marker enabled
detection of VSMC grafted in vivo. Increasing MOI led to
increased production of TGF1 in the first 6 days, followed
by an acute drop in production (Fig 1). Infection with MOI
100 to 900 decreased cell proliferation (Fig 2). This phe-
nomenon was observed with both vectors, which suggests
that it is related to the viral infection itself rather than
caused by an autocrine or paracrine effect of rTGF1.
rTGF1 recovered from infected cells in vitro was biologi-
cally active, as shown by increased in collagen synthesis and
inhibition of proliferation of MLEC-32. However, colla-
gen synthesis was more stimulated at low MOI, a phenom-
enon that could relate to cytotoxicity of viral infection at
high MOI. The inhibitory effect of rTGF1 on prolifera-
tion was gradually lost over time, and the biologic activity
was much less than expected from the quantity of immu-
noreactive rTGF1 recovered in the supernatants as as-
sessed with ELISA. The acidification required to measure
rTGF1 in the supernatants leads to quantification of total
immunoreactive rTGF1, including latent and active
forms. TGF1 is secreted as an inactive complex. A small
latent complex referred to as latency-associated peptide
(LAP) is non-covalently bound to a disulfide-link dimer of
the N-terminal part of pro-TGF. A large latent complex
contains latent TGF binding proteins disulfide-linked to
LAP. The LAP proteins confer stability, and latent TGF
binding proteins contribute to secretion and targeting of
latent TGF1.
28 The latency process is a restrictive step
toward the biologic activity of TGF1, and increased levels
of TGF1 production are not necessarily associated with
higher levels of activity.27 Producing a constitutive active
form of rTGF1 with mutated complementary DNA de-
signed to overcome the latent secretory process may pro-
vide a solution to this problem.26
Free TGF1 has a half-life of about 2 minutes.
29 De-
spite stability provided by the latent complex the half-life
remains short (90 minutes). Autotransplantation of trans-
duced VSMC is a means of providing sustained delivery of
short-lived growth factors. We have not proved that
rTGF1 secreted in vivo by transplanted VSMC is biolog-
ically active, and such a task under these conditions would
be virtually impossible. In vivo gene retention, as assessed
by GFP expression, persisted up to 3 weeks, but decreased
significantly over time. Similarly, Western blot analysis
demonstrated that the band corresponding to the molecu-
lar weight of “active” rTGF1 was almost undetectable at 3
weeks. Transient expression is expected from an adenoviral
vector infection, and a retroviral vector could be necessary
for more sustained gene expression. However, gene expres-
sion for 2 to 3 weeks may be sufficient to reverse the
evolution toward aneurysm recurrences usually observed in
our model, because recanalization after coil occlusion of
arteries consistently occurs within 2 weeks.3
Use of sponges seeded with a large number of cells is
not a realistic option for endovascular treatment of intra-
cranial aneurysm in clinical practice. Technical limitations
related to endovascular cell grafting may be more readily
overcome in aortic aneurysms, which can be reached di-
rectly with larger devices, than with intracranial aneurysms.
This strategy could consequently find a faster clinical appli-
cation as an adjunctive technique to stent-graft repair. In
addition to the delay necessary for autologous cell harvest-
ing and culturing, which does not allow urgent treatment
of aneurysm, potential difficulties related to the long chain
of manipulations, eg, inefficient primary cultures, in vitro
contaminations, and inefficient endovascular transplant
techniques, are drawbacks to this strategy. One important
problem with use of an adenoviral vector for clinical trials
remains the presence of residual viral antigens, which may
trigger an immune response, resulting in elimination of
infected cells and inflammation in surrounding tissues. The
possibility of preexisting immunity against adenovirus is
also a concern.
Direct in situ viral infection is difficult to conceive,
because potential cellular candidates for gene transfer have
not reached the aneurysm neck at embolization, and there-
fore uptake of gene delivery vectors by target cells may not
be possible. An ingenious strategy was proposed to over-
come the potential problems related to in situ approaches,
with coils as the carrier of the genetic material.30
Aneurysms treated with untransduced VSMC grafts
have shown improved results at 3 weeks, compared with
aneurysms treated with fibrinogen-coated sponges or bare
sponges.15 Thus we believe that benefits found in the
GFP-expressing controls were due to early presence of
numerous grafted VSMC rather than to a nonspecific effect
of the adenoviral infection or the GFP protein. In the
present study, we could not show an added benefit of
overexpression of TGF1, as compared with GFP only, at
least in this model. Initial angiographic results were im-
proved with cell grafts than with controls, and initial results
have an important effect on evolution of aneurysms over
time.14 Thus improved results at 3 weeks with cell grafts
may be caused by confounding factors, eg, increased
thrombogenicity of cellular sponges as compared with con-
trols. We believe that intra-aneurysmal implantation of
collagen-producing cells could modify the thrombogenic
and cellular events involved in healing mechanisms and
thus improve results of endovascular treatment.
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CONCLUSION
Endovascular cell grafting is a potential means to over-
come aneurysm recurrence after embolization. VSMC can
be effectively transduced to secrete rTGF1 when trans-
planted into aneurysms, but potential benefits from TGF1
overexpression, as well as techniques for targeted delivery
to the site of the aneurysm, require further investigation.
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